scholarly journals Pravastatin Improves Angiogenic Factors and Feto- Placental Doppler in Pregnancy with Early Severe Fetal Growth Restriction: A Case Report

2021 ◽  
Vol 4 (4) ◽  
Author(s):  
Manel Mendoza
Keyword(s):  
Case Report ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Angiogenic Factors ◽  
Growth Restriction ◽  
In Pregnancy

scholarly journals Maternal sirolimus therapy and fetal growth restriction

2021 ◽  
Vol 8 (2) ◽  
pp. 19-24
Author(s):  
Sangay Tshering ◽  
Namkha Dorji ◽  
Youden Sonam
Keyword(s):  
Case Report ◽  
Signaling Pathway ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Mtor Signaling ◽  
Growth Restriction ◽  
Mtor Signaling Pathway ◽  
Epigenetic Modulation ◽  
In Pregnancy

Fetal growth restriction associated with continued maternal sirolimus therapy in pregnancy has not been reported. We hereby present a case of maternal sirolimus therapy resulting in fetal growth restriction and propose a multi-hit model. This hypothetic model is based on inhibition of mTOR signaling pathway and epigenetic modulation. This case report adds to the paucity of literature on continued monotherapeutic maternal sirolimus in pregnancy and its adverse fetal effects.

The secrets of placental mosaicism: clinical observation of the full form of confined placental trisomy 22 and literature review

2020 ◽  
Author(s):  
I.V. Komarova, A.A. Nikiforenko, A.V. Fedunyak
Keyword(s):  
Prenatal Diagnosis ◽  
Literature Review ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Clinical Observation ◽  
Growth Restriction ◽  
Favorable Outcome ◽  
Full Form ◽  
Placental Mosaicism ◽  
In Pregnancy

Literature reports of placental mosaicism, including trisomy 22, were analyzed. The chance of correlation of placental aneuploidy with fetus aneuploidy, also the probability of complications in pregnancy and fetal growth restriction and postnatal patients growth in the cases of confined placental mosaicism, were demonstrated. The case of prenatal diagnosis of confined placental mosaicism of trisomy 22 with favorable outcome is presented. The necessity of cytogenic assay of amniocytes and fetal lymphocytes in the case of placental heteroploidy diagnosis was emphasized.

scholarly journals The use of sildenafil in severe early-onset fetal growth restriction: a case report and review of current literature

2018 ◽  
Vol 3 (3) ◽  
Author(s):  
Geoffrey H Gordon ◽  
Danielle M Berdahl ◽  
Kara K Hoppe ◽  
Kathleen M Antony
Keyword(s):  
Case Report ◽  
Fetal Growth ◽  
Current Literature ◽  
Fetal Growth Restriction ◽  
Early Onset ◽  
Growth Restriction

scholarly journals Dietary interventions for fetal growth restriction - therapeutic potential of dietary nitrate supplementation in pregnancy

2017 ◽  
Vol 595 (15) ◽  
pp. 5095-5102 ◽  
Author(s):  
Elizabeth Cottrell ◽  
Teresa Tropea ◽  
Laura Ormesher ◽  
Susan Greenwood ◽  
Mark Wareing ◽  
...  
Keyword(s):  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Therapeutic Potential ◽  
Growth Restriction ◽  
Dietary Interventions ◽  
Dietary Nitrate ◽  
Nitrate Supplementation ◽  
In Pregnancy

scholarly journals Multivariable evaluation of maternal hemodynamic profile in pregnancy complicated by fetal growth restriction: prospective study

2019 ◽  
Vol 54 (6) ◽  
pp. 732-739 ◽  
Author(s):  
D. D. Di Martino ◽  
E. Ferrazzi ◽  
M. Garbin ◽  
F. Fusè ◽  
T. Izzo ◽  
...  
Keyword(s):  
Prospective Study ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Growth Restriction ◽  
Hemodynamic Profile ◽  
In Pregnancy

Evaluating the Effect of Pravastatin in Early-Onset Fetal Growth Restriction: A Nonrandomized and Historically Controlled Pilot Study

2020 ◽  
Author(s):  
Manel Mendoza ◽  
Raquel Ferrer-Oliveras ◽  
Erika Bonacina ◽  
Pablo Garcia-Manau ◽  
Carlota Rodo ◽  
...  
Keyword(s):  
Pilot Study ◽  
Fetal Growth ◽  
Pregnancy Outcomes ◽  
Fetal Growth Restriction ◽  
Early Onset ◽  
Maternal Serum ◽  
Angiogenic Factors ◽  
Interquartile Range ◽  
Growth Restriction ◽  
Control Group

Objective This study aimed to analyze the effect of pravastatin on angiogenic factors, feto–maternal Doppler findings and pregnancy outcomes in women with early-onset fetal growth restriction (FGR) treated with pravastatin compared with nontreated controls. Study Design This was a pilot study conducted between March 2016 and September 2017. Women with single pregnancies and FGR diagnosed at ≤ 28 weeks of gestation were offered 40 mg of pravastatin daily. Doppler progression, soluble fms-like tyrosine kinase 1 (sFlt-1)/placental growth factor (PlGF) values, and pregnancy outcomes were assessed and compared with consecutive historical controls. Controls were matched to treated women for gestational age, maternal characteristics, maternal and obstetric history, Doppler severity classification, and angiogenic factors at diagnosis. The sFlt-1/PlGF was measured in maternal serum at two different times: before pravastatin was started (ratio M0) and during pravastatin treatment (ratio M1). Doppler severity was classified into four categories: normal, mild, moderate, and severe. Results A total of 38 women were enrolled in this study. No differences were observed in baseline characteristics between groups. However, when compared with the ratio M0, M1 was increased by a median (interquartile range) of 67.0 (−34.8 to 197.3) in the control group but decreased by a median (interquartile range) of −10.1 (−53.1 to −0.07) in the pravastatin treated group (p < 0.001). No significant differences were observed in Doppler progression throughout pregnancy. Median interval from diagnosis to delivery was extended by 16.5 days, the median newborn birthweight was increased from 1,040 to 1,300 g, and the number of women with preeclampsia decreased from 9 (47.4%) to 6 (31.6%) in treated women; however, these trends were not statistically significant. Conclusion In women with early-onset FGR, treatment with pravastatin 40 mg daily was associated with significant improvement in the angiogenic profile. Additionally, median pregnancy duration and median birthweight increased and the incidence of PE was reduced in treated women. Nevertheless, since this pilot study was underpowered, none of these differences were statistically significant. Key Points

scholarly journals Non-targeted urinary metabolomics in pregnancy and associations with fetal growth restriction

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Chelsea M. Clinton ◽  
James R. Bain ◽  
Michael J. Muehlbauer ◽  
YuanYuan Li ◽  
Leping Li ◽  
...  
Keyword(s):  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Growth Restriction ◽  
In Pregnancy

scholarly journals Potential effects of transdermal nitric oxide donor on fetal growth restriction and oligohydramnios: A case report

2020 ◽  
Vol 8 (12) ◽  
pp. 3288-3293
Author(s):  
Tsuyoshi Murata ◽  
Toma Fukuda ◽  
Tetsu Sato ◽  
Aya Kanno ◽  
Hyo Kyozuka ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Case Report ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Growth Restriction ◽  
Nitric Oxide Donor
Sign in / Sign up

Export Citation Format

Share Document